Agilon health (AGL) is back in focus after expanding its relationship with Family Practice Center in Pennsylvania, adding the group to one of its Senior Health Connect Accountable Care Organizations.
The expansion news follows a sharp run-up in agilon health’s share price this year. The year-to-date share price return is 429.45%, while the 90-day share price return is down 20.20%. The 1-year total shareholder return is 215.61%, in contrast to a 3-year total shareholder return that has fallen 80.69%.
Capitalize on the renewed attention around agilon health by scanning a curated set of health-focused operators in value-based care and senior services through 37 healthcare AI stocks.Bulls point to agilon health’s value-based model, recent ACO savings record, and this new Pennsylvania deal. Bears focus on the long history of share price volatility. Which story does the valuation currently lean toward?
Analysts following agilon health see a fair value of $110.92 per share, above the last close at $89.16, which sets a clear valuation gap that hinges on whether the business can convert its model into sustainable profits.
Strategic investments in advanced data analytics, AI-driven platforms, and enhanced burden-of-illness and quality assessment programs are improving the identification and management of high-risk patients, which should contribute to improved risk adjustment, better medical cost control, and higher net margins and earnings beginning in 2026. Negotiated improvements in contract economics with payer partners, including reduced Part D risk exposure, escalation of quality incentives, and refined supplemental benefit sharing, are expected to support higher profitability and margin recovery in future periods.
See why 10 investors see agilon health as 20% undervalued.
Result: Fair Value of $110.92 (UNDERVALUED)
Still, the agilon health story carries pressure points, including ongoing Medicare Advantage membership declines and heavy reliance on a few payer contracts that could reset economics.
Find out about the key risks to this agilon health narrative.
Sentiment on agilon health is split, with clear concerns and also real optimism around the thesis, so move quickly, review the numbers yourself, and weigh both sides through 4 key rewards and 1 important warning sign
Do not stop with agilon health. Broader opportunities are available, and using a focused screener can help you quickly surface candidates that match your investing style.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com